3401 On Other Exchanges
Symbol
Exchange
3401 is not on other exchanges.

teijin ltd (3401) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TEIJIN LTD (3401)

Related News

No related news articles were found.

teijin ltd (3401) Related Businessweek News

No Related Businessweek News Found

teijin ltd (3401) Details

Teijin Limited provides solutions to transportation, information and electronics, safety and protection, environment and energy, and healthcare areas worldwide. The company’s Advanced Fibers and Composites segment offers para-aramid, meta-aramid, polyester, and polyethylene naphthalate (PEN) fibers; synthetic leather; carbon fibers and intermediate materials; carbon fiber reinforced composites; and flame-resistant fibers. Its Electronics Materials and Performance Polymer Products segment provides polycarbonate (PC) resins, PC/ABS and PC/AS polymer alloys, PEN resins, polyethylene terephthalate (PET) resins, polybutylene naphthalete resins, bromine series flame retardants, PET and PEN films, processed films, monomers, and polymers. The company’s Healthcare segment offers Bonalon and Onealfa for the treatment of osteoporosis; Synvisc to treat knee osteoarthritis pain; sonic accelerated fracture healing systems; Mucosolvan, an expectorant; and Alvesco, an inhaled corticosteroid agent for asthma. This segment also provides oxygen concentrators for home oxygen therapy; continuous positive airway pressure units; NIP NASAL, a non-invasive positive pressure ventilator; AutoSet CS, an adaptive servo-ventilator; Feburic to treat hyperuricemia and gout; Tricor for hyperlipidemia; and Venilon for Intravenous immunoglobulin preparation. Its Trading and Retail segment sells and trades fibrous raw material, apparel, industrial materials, and performance polymer products. The company also offers IT services in the healthcare field, Web-based enterprise resource planning, and digital content management services; content distribution services for mobile phones and smartphones, and e-commerce services; and polyester raw materials and polymerization services. Teijin Limited was founded in 1918 and is headquartered in Osaka, Japan.

15,756 Employees
Last Reported Date: 06/22/16
Founded in 1918

teijin ltd (3401) Top Compensated Officers

Chief Executive Officer, President, Member of...
Total Annual Compensation: ¥102.0M
Compensation as of Fiscal Year 2016.

teijin ltd (3401) Key Developments

Teijin Ltd. Presents at Mizuho Investment Conference - Tokyo, Sep-12-2016

Teijin Ltd. Presents at Mizuho Investment Conference - Tokyo, Sep-12-2016 . Venue: Prince Park Tower Hotel, 4-8-1, Shibakoen, Minato-ku, Tokyo 105-8563, Japan.

Teijin Seeks Acquisition

Teijin Ltd. (TSE:3401) is seeking to pursue new merger and acquisition opportunities in a bid to optimise local production for local consumption and reinforce its production capabilities around the world.

Teijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan

Teijin Limited and Versartis, Inc. announced that the companies and their wholly owned subsidiaries have entered into an exclusive license and supply agreement for the development and commercialization of somavaratan (VRS-317) in Japan. Somavaratan is currently the longest acting growth hormone product in development, with a twice-monthly dosing schedule being evaluated in clinical trials, and may be the first long-acting entrant to the Japanese market. In pediatric GHD, the J14VR5 Phase 2/3 trial of somavaratan is underway in Japan and the Phase 3 VELOCITY trial in the U.S., Canada and Europe is expected to complete enrollment in mid-August 2016, with data anticipated in the third quarter 2017. In adult GHD, the Phase 2 VITAL trial in the U.S., Europe and Australia has completed enrollment and initial top-line data are expected during the second half of 2016. Under the terms of the agreement, Teijin will receive an exclusive license to commercialize and further develop somavaratan long acting growth hormone in Japan, while Versartis retains exclusive rights to somavaratan in the rest of the world. Versartis GmbH, a subsidiary of Versartis, Inc., will receive an upfront payment of $40 million and is eligible to receive up to $125 million in milestone payments, as follows: development milestone of $35 million, regulatory milestones up to $55 million and sales milestones up to $35 million.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

3401 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3401.
View Industry Companies
 

Industry Analysis

3401

Industry Average

Valuation 3401 Industry Range
Price/Earnings 14.1x
Price/Sales 0.5x
Price/Book 1.4x
Price/Cash Flow 10.7x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TEIJIN LTD, please visit www.teijin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.